US · guidance

CMS Pub. 100-03, ch. 1, § 20.22

Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for

activein force · 2026-08-25 – presentas-observed

Treatment of Atherosclerosis

(Rev. 1, 10-03-03)

CIM 45-20

The use of EDTA as a chelating agent to treat atherosclerosis, arteriosclerosis, calcinosis,

or similar generalized condition not listed by the FDA as an approved use is not covered.

Any such use of EDTA is considered experimental. See §20.21 for an explanation of this

conclusion.

History

(Rev. 1, 10-03-03)

Provenance

Source: cms.gov
Retrieved: 2026-08-25
Edition: iom-2026-08-25
Content hash: 28dd70976d2bcb9d44c3298e3c4955db878430f947e8e6519c7ef80e70bf100b

View the official source →

The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.

Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.

Coverage · API docs